XYLOCOR THERAPEUTICS INC

Malvern, PA · Founded 2013 · Biotech · Private

Gene therapy vectors and treatments for cardiovascular disease

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · xylocor.com

Sector: Biotech
Headquarters: Malvern, PA
Founded: 2013
Latest Form D: $4M, Jan 2021
Total capital: $21.7M

Federal grants: $300K; 1 award · 2023; Rank in peer group#8 of 392
Private capital raised: $21.4M; 6 Form D · last Jan 2021; 69 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 2 pending

Capital timeline

Latest events

May 2023Federal grantHealth and Human S · Phase I · Combined Pro-Plasticity Reprogramming Strategies to Enhance Post-Infarction Myocardial Recovery$300K
Jan 2021Private capital raisedForm D · SEC · 6th filing$4M
Oct 2018Private capital raisedForm D · SEC · 5th filing$16.8M
Jul 2018Private capital raisedForm D · SEC · 4th filing$200K
Mar 2018Private capital raisedForm D · SEC · 3rd filing$60K
Dec 2017Private capital raisedForm D · SEC · 2nd filing$100K
Nov 2016Private capital raisedForm D · SEC · 1st filing$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

Federal grants#8 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Aidan F. KingDirectorNamed in SEC Form D filings
Albert GianchettiExecutive Officer, DirectorNamed in SEC Form D filings
Fouad Azzam, Ph.D.DirectorNamed in SEC Form D filings
Glenn BatchelderDirectorNamed in SEC Form D filings
James CohenDirectorNamed in SEC Form D filings
Michael F. Powell, Ph.D.DirectorNamed in SEC Form D filings

Show all 8 people

Todd RosengartDirectorNamed in SEC Form D filings
Todd K. Rosengart, M.D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 2

Apr 11, 2024PendingEpicardial Delivery of Gene TherapyUSPTOApplication 17767524
PendingEpicardial Delivery of Gene TherapyUSPTOApplication 62912958

EPIODYNE, INC.Similar federal contract value in Biotech · null in contracts
AGGAMIN PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
Palvella Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Tracon Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Holobiome, Inc.Similar federal contract value in Biotech · null in contracts
KHLORIS BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.